U.S. Patent Trial and Appeal Board Institutes Inter Partes Review Based on Geneoscopy's Petition Challenging Validity of a Second Patent Asserted by Exact Sciences
Portfolio Pulse from
The U.S. Patent Trial and Appeal Board has initiated an inter partes review of a patent owned by Exact Sciences, following a petition by Geneoscopy. This review challenges the validity of U.S. Patent No. 11,970,746.
February 18, 2025 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The U.S. Patent Trial and Appeal Board has initiated a review of a patent owned by Exact Sciences, following a challenge by Geneoscopy. This could impact Exact Sciences' intellectual property and market position.
The initiation of an inter partes review suggests potential vulnerabilities in Exact Sciences' patent, which could affect its competitive edge and market valuation if the patent is invalidated.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80